METTL3 and breast cancer: Interfering this pathway or reducing METTL3 expression could potentially inhibit the malignant behavior of BC cells.13 YTHDC1 has also gained attention for its roles in BC, where restoring YTHDC1 expression can increase BC cell sensitivity to chemotherapeutic agents such as cisplatin.43 Combining YTHDC1 modulation with autophagy inhibitors, such as chloroquine, may further suppress BC cell proliferation, providing a new strategy to enhance treatment efficacy.17